HC Wainwright Issues Pessimistic Outlook for ELVN Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Enliven Therapeutics in a research note issued on Thursday, May 15th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.60) for the quarter, down from their previous forecast of ($0.53). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.45) EPS and FY2026 earnings at ($2.81) EPS.

Separately, Jones Trading reduced their price target on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a report on Friday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Enliven Therapeutics presently has an average rating of “Buy” and an average price target of $37.25.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $16.86 on Monday. The firm has a market capitalization of $827.30 million, a price-to-earnings ratio of -8.87 and a beta of 1.07. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $30.03. The business has a 50 day simple moving average of $18.84 and a 200-day simple moving average of $21.65.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06).

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its holdings in Enliven Therapeutics by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company’s stock worth $5,892,000 after purchasing an additional 6,611 shares during the period. Wellington Management Group LLP increased its holdings in Enliven Therapeutics by 15.3% during the 4th quarter. Wellington Management Group LLP now owns 80,916 shares of the company’s stock worth $1,821,000 after purchasing an additional 10,746 shares during the period. Vanguard Group Inc. increased its holdings in Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock worth $44,452,000 after purchasing an additional 55,283 shares during the period. Franklin Resources Inc. purchased a new position in Enliven Therapeutics during the 3rd quarter worth $559,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Enliven Therapeutics during the 4th quarter worth $97,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the sale, the chief operating officer now directly owns 323,310 shares in the company, valued at approximately $6,931,766.40. This represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the transaction, the chief financial officer now owns 13,000 shares in the company, valued at $265,330. The trade was a 20.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 76,111 shares of company stock worth $1,493,145. 29.20% of the stock is currently owned by company insiders.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.